Amyris, Inc., a leading synthetic biotechnology company in Clean Health and Beauty markets and IDRI (Infectious Disease Research Institute) signed a binding term sheet for a planned COVID-19 RNA (ribonucleic acid) vaccine technology program. The program combines IDRI’s expertise in combating infectious diseases with Amyris’ fermentation platform technology, with the goal to create semi-synthetic squalene-based adjuvants at scale.
“At Union level, the European Green Deal is surely a clear and strong signal to many industries, and this will help our clients to gain further competing edges vs parties that still struggle to understand the benefit of implementing biosynthesis into their processes as tool to increase their competitiveness and sustainability.” To say it – in this exclusive interview with Il Bioeconomista – is Cyrille Pauthenier, Ceo and co-founder of Abolis, an industrial biotech company located in France. Pauthenier is graduated from École Normale Supérieure de Paris where he studied fundamental chemistry and biology. In 2011, he specialized in synthetic biology. In 2014, after obtaining his Ph.D., Cyrille co-founded Abolis, with the aim of using biology to accelerate the ecological transition of chemical industry.
Interview by Mario Bonaccorso
International investor groups, including the Asia Investor Group on Climate Change (AIGCC), have encouraged global governments to ensure they are planning for a sustainable recovery from the COVID-19 pandemic by factoring in climate change risk into economic recovery plans.
“Today we can produce PLA directly from glucose, but in the future, we will obtain it starting from organic wastes and, looking more forward, from carbon dioxide”. To say it – in this interview with Il Bioeconomista – is Danilo Porro, professor at University of Milano Bicocca and President of Galatea Biotech, one of the most innovative Italian industrial biotech start-up company. Headquartered in Milan, Galatea has developed a new process to produce PLA from glucose.
Interview by Mario Bonaccorso
This year’s third World Bioeconomy Forum (WCBEF) will be broadcast live from Ruka on September 10th, 2020. Due the current global pandemic the Advisory Board has decided to take a cautious approach and will provide delegates with a high-quality, interactive virtual event which will be moderated from Ruka in Finland. The event will deliver the usual high-level content, while at the same time as providing a unique experience for all bioeconomy stakeholders from around the world.
The full programme will be six hours in duration and will consist of four dedicated sessions: Regulators and Climate Change, Global Leaders and Financial World, Bioproducts around us, and Looking to the Future. The audience can contribute interactively on message walls and arrange online meetings with the other participants using the technology and channels provided. Continue reading
Braskem, producer of polyolefins and biopolymers, is meeting the polypropylene raw material needs of medical manufacturing customers for the production of respiratory masks as well as protective medical gear.
“Within the bioeconomy we have a massive range of new tools and opportunities to exploit this chaotic time.” To say it – in this long exclusive interview with Il Bioeconomista – is Tony Duncan, CEO of Circa Group, the Australia-based biochemical company, which is revolutionizing the traditional chemical sector. With him we talk about his company and the bioeconomy in the COVID-19 age.
Interview by Mario Bonaccorso
An alliance has been launched in the European Parliament on the back of calls from 12 EU environment ministers who have signed an appeal for a green recovery from the COVID-19 pandemic. The “green recovery alliance” was launched last Monday at the initiative of Pascal Canfin, a French centrist MEP who chairs the European Parliament’s committee on environment and public health.
Clariant, a focused and innovative specialty chemical company, today announced it has started monthly production of 2 million liters of disinfectant at its facilities in Gendorf, Germany. This disinfectant is then directly or via repacking partners provided to regional hospitals and other vital institutions in Bavaria, who are currently facing limited availability of this critical product during the COVID-19 outbreak.
“We also need to careful that the warning bells don’t go unnoticed as we try to rebuild our way of life in the same mold as before. Already we are hearing murmurings about a need for cheap (and fossil) energy to stimulate ailing virus hit sectors. We do not need to go back in time, we need to move forward. Hopefully COVID will have taught us how bad things can get when we do not think, do not plan, do not collaborate, do not listen to the science, do not listen to early warnings. But the most important lesson, I think, is that through individual action and caring for others, people who were healthy and in “low” risk groups, stayed home. They were sacrificing for others; they were not thinking about themselves.”
To say it – in this exclusive interview with Il Bioeconomista – is Jennifer Holmgren, CEO of LanzaTech.
Interview by Mario Bonaccorso
IL BIOECONOMISTA 